| 1 |
33239432 | FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions. | 2021 Apr 15 |
1 |
| 2 |
34045295 | FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions. | 2021 Oct 15 |
1 |
| 3 |
32846060 | Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. | 2020 Aug 27 |
1 |
| 4 |
28082048 | RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients. | 2017 Jul |
2 |
| 5 |
24342537 | Validation of a commercially available kit to detect anti-phosphatidylserine/prothrombin antibodies in a cohort of systemic lupus erythematosus patients. | 2014 Mar |
1 |
| 6 |
25085632 | Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. | 2014 Aug 1 |
1 |